Piramal Pharma Limited (PPLPHARMA) - Total Liabilities
Based on the latest financial reports, Piramal Pharma Limited (PPLPHARMA) has total liabilities worth Rs-81.63 Billion INR (≈ $-882.76 Million USD) as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check PPLPHARMA cash and liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Piramal Pharma Limited - Total Liabilities Trend (2021–2026)
This chart illustrates how Piramal Pharma Limited's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see Piramal Pharma Limited assets under control.
Piramal Pharma Limited Competitors by Total Liabilities
The table below lists competitors of Piramal Pharma Limited ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Nanjing Tanker Corp
SHG:601975
|
China | CN¥1.48 Billion |
|
XJ Electric Co Ltd
SHE:000400
|
China | CN¥12.28 Billion |
|
OceanaGold Corporation
F:RQQ
|
Germany | €647.50 Million |
|
Aperam SA
MC:APAM
|
Spain | €3.49 Billion |
|
KINGSOFT C.H.LTD. DL-001
F:KS70
|
Germany | €17.42 Billion |
|
Seek Ltd
AU:SEK
|
Australia | AU$1.88 Billion |
|
Vista Energy S.A.B. de C.V.
BA:VIST
|
Argentina | AR$5.78 Billion |
|
National Storage REIT
AU:NSR
|
Australia | AU$2.49 Billion |
Liability Composition Analysis (2021–2026)
This chart breaks down Piramal Pharma Limited's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See how leveraged is Piramal Pharma Limited's balance sheet to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | N/A | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.00 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | N/A | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Piramal Pharma Limited's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Piramal Pharma Limited (2021–2026)
The table below shows the annual total liabilities of Piramal Pharma Limited from 2021 to 2026.
| Year | Total Liabilities | Change |
|---|---|---|
| 2026-03-31 | Rs98.02 Billion ≈ $1.06 Billion |
+29.80% |
| 2025-03-31 | Rs75.52 Billion ≈ $816.73 Million |
+2.05% |
| 2024-03-31 | Rs74.00 Billion ≈ $800.33 Million |
-4.50% |
| 2023-03-31 | Rs77.49 Billion ≈ $838.03 Million |
+27.02% |
| 2022-03-31 | Rs61.00 Billion ≈ $659.74 Million |
+268.37% |
| 2021-03-31 | Rs16.56 Billion ≈ $179.10 Million |
-- |
About Piramal Pharma Limited
Piramal Pharma Limited operates as a pharmaceutical company in the United States, Europe, Japan, India, and internationally. The company offers a portfolio of pharmaceutical products and services through global development and manufacturing facilities. It also operates contract development and manufacturing organization that provides services across the drug life cycle, including discovery, devel… Read more